European Growth Companies With High Insider Ownership

Yahoo

5 days ago

As European markets experience a positive upswing, with the STOXX Europe 600 Index climbing on strong corporate earnings and optimism surrounding geopolitical tensions, investors are increasingly looking towards growth companies with high insider ownership as potential opportunities. In this context, stocks where insiders hold significant stakes can be particularly appealing, as they often indicate confidence in the company's future prospects and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
Name
Insider Ownership
Earnings Growth
Pharma Mar (BME:PHM)
11.8%
44.2%
MedinCell (ENXTPA:MEDCL)
13.9%
94%
Marinomed Biotech (WBAG:MARI)
29.7%
20.2%
KebNi (OM:KEBNI B)
38.3%
67.4%
Elliptic Laboratories (OB:ELABS)
24.4%
79%
CTT Systems (OM:CTT)
17.5%
37.9%
Circus (XTRA:CA1)
24.7%
72.6%
CD Projekt (WSE:CDR)
29.7%
39.5%
Bonesupport Holding (OM:BONEX)
10.4%
62.3%
Bergen Carbon Solutions (OB:BCS)
12%
63.2%
Click here to see the full list of 213 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's uncover some gems from our specialized screener.
2020 Bulkers
Simply Wall St Growth Rating: ★★★★★☆
Overview: 2020 Bulkers Ltd. owns and operates large dry bulk vessels worldwide, with a market cap of NOK 3.11 billion.
Operations: The company generates revenue from operating large dry bulk vessels across global markets.
Insider Ownership: 11.2%
2020 Bulkers, a company with significant insider ownership, is expected to see earnings grow significantly at 30.9% annually, outpacing the Norwegian market. Despite trading at a substantial discount to its estimated fair value and projecting strong revenue growth of 14.1%, recent financial performance has been weak with declining sales and net income compared to last year. The company's high dividend yield appears unsustainable given current earnings coverage and its elevated debt level poses potential risks.
Click to explore a detailed breakdown of our findings in 2020 Bulkers' earnings growth report.
Our valuation report here indicates 2020 Bulkers may be undervalued.
RaySearch Laboratories
Simply Wall St Growth Rating: ★★★★★☆
Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer treatment globally, with a market cap of SEK9.43 billion.
Operations: The company's revenue is primarily derived from its Healthcare Software segment, which generated SEK1.25 billion.
Insider Ownership: 17.6%
RaySearch Laboratories, with high insider ownership, is forecasted to achieve significant earnings growth of 24.9% annually, surpassing the Swedish market. Despite a recent decline in quarterly sales and net income, the company remains focused on innovation and strategic partnerships. Its oncology software solutions like RayStation and RayCare continue to gain traction globally. While trading near industry average valuations, its forward-looking revenue growth is expected at 13.6%, outpacing the broader Swedish market's rate.
Delve into the full analysis future growth report here for a deeper understanding of RaySearch Laboratories.
Our comprehensive valuation report raises the possibility that RaySearch Laboratories is priced higher than what may be justified by its financials.
Nagarro
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nagarro SE, with a market cap of €646.42 million, provides digital product engineering and technology solutions in Germany, the United States, and internationally through its subsidiaries.
Operations: Nagarro SE generates its revenue through digital product engineering and technology solutions across Germany, the United States, and other international markets.
Insider Ownership: 12.3%
Nagarro, with substantial insider ownership, is projected to experience significant earnings growth of 23.6% annually, outpacing the German market. Despite a recent dip in net income for the first half of 2025 and lowered revenue guidance for the year, it trades at good value compared to its peers and below its estimated fair value. The company has been added to key German indices like TECDAX and SDAX, reflecting its solid market position.
Click here to discover the nuances of Nagarro with our detailed analytical future growth report.
The analysis detailed in our Nagarro valuation report hints at an deflated share price compared to its estimated value.
Where To Now?
Gain an insight into the universe of 213 Fast Growing European Companies With High Insider Ownership by clicking here.
Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OB:2020 OM:RAY B and XTRA:NA9.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email [e-mail]